<DOC>
	<DOC>NCT00116688</DOC>
	<brief_summary>The purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. Participants must have previously completed a romiplostim ITP study.</brief_summary>
	<brief_title>Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Must have previously completed a romiplostim ITP study Platelet count â‰¤ 50 x 10 ^9/L Written informed consent Bone marrow stem cell disorder or new active malignancies diagnosed since enrollment in the previous romiplostim ITP study Received any alkylating agents within 4 weeks before screening visit or anticipated use during the time of the proposed study Currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous romiplostim ITP study), or subject is receiving other investigational agent(s) other than romiplostim Not using adequate contraceptive precautions Not available for followup assessments Has any kind of disorder that compromises the ability of the participant to give informed consent and does not have a legallyacceptable representative and/or is unable to comply with study procedures.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Immune (Idiopathic) Thrombocytopenic Purpura (ITP)</keyword>
	<keyword>Thrombocytopenic</keyword>
</DOC>